In clinical trials, the response to epidermal growth factor receptor (EGFR) inhibitors, such as gefitinib, has varied widely, ranging from rare in breast cancers to 10–30% in metastatic non-small-cell lung carcinoma (NSCLC) (Dancey and Freidlin, 2003). This evidence concerns the gene EGFR and breast cancer.